1.09
-0.01(-0.91%)
Currency In USD
| Previous Close | 1.1 |
| Open | 1.11 |
| Day High | 1.14 |
| Day Low | 1.08 |
| 52-Week High | 3.78 |
| 52-Week Low | 0.86 |
| Volume | 2.25M |
| Average Volume | 3.81M |
| Market Cap | 241.84M |
| PE | -0.99 |
| EPS | -1.1 |
| Moving Average 50 Days | 1.25 |
| Moving Average 200 Days | 1.71 |
| Change | -0.01 |
If you invested $1000 in Allogene Therapeutics, Inc. (ALLO) since IPO date, it would be worth $44 as of August 18, 2025 at a share price of $1.1. Whereas If you bought $1000 worth of Allogene Therapeutics, Inc. (ALLO) shares 5 years ago, it would be worth $29.67 as of August 18, 2025 at a share price of $1.1.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update
GlobeNewswire Inc.
Aug 06, 2025 12:30 PM GMT
Conference Call and Webcast Scheduled for August 13, 2025 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the
Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma
GlobeNewswire Inc.
Aug 01, 2025 12:30 PM GMT
Lymphodepletion Regimen Selection Made in Conjunction with the ALPHA3 Data and Safety Monitoring Board (DSMB) and Steering Committee, and in Consultation with the FDA Following an ALLO-647-Related Death in the FCA (FC plus ALLO-647) Lymphodepletion A
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO
GlobeNewswire Inc.
Jun 01, 2025 2:45 PM GMT
Data Highlights Transformative Promise of CAR T in Solid TumorsPhase 1 Trial with ALLO-316 Demonstrated Potential to Provide Meaningful Clinical Benefit in Patients with CD70 TPS ≥ 50% Advanced or Metastatic RCC A Single Dose of ALLO-316 Achieved